Trials / Completed
CompletedNCT00698464
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
A Phase I, Open-label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of varying degrees of hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of pasireotide s.c. in subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pasireotide | Single subcutaneous injection of 600 µg of Pasireotide. |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-04-01
- First posted
- 2008-06-17
- Last updated
- 2020-12-21
Locations
4 sites across 4 countries: United States, Belgium, Germany, South Africa
Source: ClinicalTrials.gov record NCT00698464. Inclusion in this directory is not an endorsement.